Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-BCMA Chimeric Antigen Receptor (CARTemis-1) T-lymphocyte Therapy in the Treatment of Patients With Multiple Myeloma in Relapse After Allogeneic Transplant: Endothelial Growth Factor Receptor Expression as a Control Mechanism of Treatment-derived Complications

NCT05982275 is registered in ClinicalTrials.gov with Fundación Pública Andaluza para la gestión de la Investigación en Sevilla as lead sponsor.

NCT NCT05982275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05982275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-BCMA Chimeric Antigen Receptor (CARTemis-1) T-lymphocyte Therapy in the Treatment of Patients With Multiple Myeloma in Relapse After Allogeneic Transplant: Endothelial Growth Factor Receptor Expression as a Control Mechanism of Treatment-derived Complications
Lead sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 30, 2024
Completion date
December 31, 2029
Enrollment
25 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic stem cell transplantation, multiple myeloma